{"organizations": [], "uuid": "c05f2fc863189eb00f7b6efa1d059bb1206b3b58", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180412.html", "section_title": "Archive News &amp; Video for Thursday, 12 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-indias-strides-shasun-gets-us-fda/brief-indias-strides-shasun-gets-u-s-fda-nod-for-cyproheptadine-hydrochloride-tablets-idUSFWN1RP04V", "country": "US", "domain_rank": 408, "title": "BRIEF-India's Strides Shasun Gets U.S. FDA Nod For Cyproheptadine Hydrochloride Tablets", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-04-12T14:29:00.000+03:00", "replies_count": 0, "uuid": "c05f2fc863189eb00f7b6efa1d059bb1206b3b58"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-indias-strides-shasun-gets-us-fda/brief-indias-strides-shasun-gets-u-s-fda-nod-for-cyproheptadine-hydrochloride-tablets-idUSFWN1RP04V", "ord_in_thread": 0, "title": "BRIEF-India's Strides Shasun Gets U.S. FDA Nod For Cyproheptadine Hydrochloride Tablets", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bangalore", "sentiment": "none"}, {"name": "u.s", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "shasun ltd", "sentiment": "negative"}, {"name": "ets", "sentiment": "none"}, {"name": "pharma inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12 (Reuters) - Strides Shasun Ltd:\n* GETS USFDA APPROVAL FOR CYPROHEPTADINE HYDROCHLORIDE TABLETS\n* PRODUCT WILL BE MANUFACTURED AT ORAL DOSAGE FACILITY AT BANGALORE\n* PRODUCT WILL BE MARKETED BY STRIDES PHARMA INC IN U.S MARKET\n* SAYS DRUG IS INDICATED TO RELIEVE ALLERGY SYMPTOMS Source text - bit.ly/2GUG4J2 Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://bit.ly/2GUG4J2", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-12T14:29:00.000+03:00", "crawled": "2018-04-13T17:32:58.005+03:00", "highlightTitle": ""}